Lorenzo Braghieri

Dr. Lorenzo Braghieri


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya
BBBruno Bohn
Bruno Bohn
AJAzka Javaid
Azka Javaid
GMGiulio M. Mondellini
Giulio M. Mondellini
LBLorenzo Braghieri
Lorenzo Braghieri
RDRyan T. Demmer
Ryan T. Demmer
Background: Trimethylamine N-oxide (TMAO)—a gut-derived metabolite—is elevated in heart failure (HF) and linked to poor prognosis. We investigated variations in TMAO in HF, left ventricular assist device (LVAD), and heart transplant (HT) and assessed its relation with inflammation, endotoxemia, oxidative stress, and gut dysbiosis. Methods: We enrolled 341 patients. TMAO, CRP (C-reactive protein), IL (interleukin)-6, TNF-α (tumor necrosis factor alpha), ET-1 (endothelin-1), adiponectin, lipopolysaccharide, soluble CD14, and isoprostane were measured in 611 blood samples in HF (New York Heart Association class I–IV) and at multiple time points post-LVAD and post-HT. Gut microbiota were assessed via 16S rRNA sequencing among 327 stool samples. Multivariable regression models were used to assess the relationship between TMAO and (1) New York Heart Association class; (2) pre- versus post-LVAD or post-HT; (3) biomarkers of inflammation, endotoxemia, oxidative stress, and microbial diversity. Results: ln-TMAO was lower among HF New York Heart Association class I (1.23 [95% CI, 0.52–1.94] µM) versus either class II, III, or IV (1.99 [95% CI, 1.68–2.30], 1.97 [95% CI, 1.71–2.24], and 2.09 [95% CI, 1.83–2.34] µM, respectively; all P 6 months: 1.99 [95% CI, 1.76–2.22] µM) and HT (>6 months: 1.86 [95% CI, 1.66–2.05] µM) were not different from symptomatic HF. After multivariable adjustments, TMAO was not associated with biomarkers of inflammation, endotoxemia, oxidative stress, or microbial diversity. Conclusions: TMAO levels are increased in symptomatic HF patients and remain elevated long term after LVAD and HT. TMAO levels were independent from measures of inflammation, endotoxemia, oxidative stress, and gut dysbiosis.

1 August 2023 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LBLorenzo Braghieri
Lorenzo Braghieri
OBOsamah Z. Badwan
Osamah Z. Badwan
WSWarren Skoza
Warren Skoza
MFMaan Fares
Maan Fares
VMVenu Menon
Venu Menon
Many patients with chronic kidney disease have chronically elevated cardiac troponin levels, and if they present with symptoms suggesting an acute coronary syndrome, it is often difficult to determine if this is the correct diagnosis. This article briefly reviews the major challenges in diagnosing acute coronary syndrome in patients with chronic kidney disease, describes the mechanisms and prognostic significance of troponin elevation in chronic kidney disease, and provides a diagnostic algorithm to risk-stratify patients with chronic kidney disease who have troponin elevation and suspected acute coronary syndrome.

12 June 2024 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
EAEmmanuel Akintoye
Emmanuel Akintoye
JDJoseph El Dahdah
Joseph El Dahdah
MDM Marwan Dabbagh
M Marwan Dabbagh
HPHardik Patel
Hardik Patel
OBOsamah Badwan
Osamah Badwan
ZPZoran B. Popovic
Zoran B. Popovic

20 June 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
CBClaudio Bravo
Claudio Bravo
JFJustin A. Fried
Justin A. Fried
JWJoshua Z. Willey
Joshua Z. Willey
AJAzka Javaid
Azka Javaid
GMGiulio M. Mondellini
Giulio M. Mondellini
PCPaolo C. Colombo
Paolo C. Colombo

21 October 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
LBLorenzo Braghieri
Lorenzo Braghieri
AYArwa Younis
Arwa Younis
CTChadi Tabaja
Chadi Tabaja
PSPasquale Santangeli
Pasquale Santangeli
TTTyler Taigen
Tyler Taigen
AHAyman A. Hussein
Ayman A. Hussein
Background: Catheter ablation is a first‐line therapy for atrial fibrillation (AF). We evaluated the impact of obstructive sleep apnea (OSA) on arrhythmia and postablation quality‐of‐life outcomes among AF subtypes. Methods: Consecutive patients undergoing AF ablation (2013–2022) at a tertiary center were enrolled and assessed for arrhythmia recurrence over 3‐year follow‐up. A subset of patients enrolled in an automated patient‐reported outcomes platform were assessed for quality of life, including Atrial Fibrillation Severity Score and AF burden (AF duration and frequency scores). Results: A total of 7020 patients were included: 3380 with paroxysmal AF (PAF) and 3640 with persistent AF (PersAF), of whom 729 and 943 had OSA, respectively (PAF: age, 66.5±10 years [69% men]; PersAF: age, 66.1±9 years [76% men]). Unlike patients with PersAF, those with PAF and OSA had higher AF recurrence (PAF: no OSA=70% versus OSA=64% [ P <0.01]; PersAF: no OSA=57% versus OSA=60% [ P =0.24]). Baseline OSA was independently associated with a 30% increased AF recurrence risk (hazard ratio, 1.30; P <0.001) among patients with PAF, but not among patients with PersAF. Significant improvement in 1‐year postablation quality of life was noted in both groups irrespective of OSA ( P <0.001 for all comparisons): (1) median AF symptom severity (PAF: no OSA 10→2, OSA 12→4; PersAF: 12→4 in both groups); and (2) median AF duration (PAF: 6.25→0 in both groups; PersAF: 10→0 in both groups); median AF frequency (PAF: 6→0 in both groups; PersAF: 9→0 in both groups). Conclusions: Baseline OSA was associated with an increased AF recurrence risk in patients with PAF, but not in those with PersAF. Catheter ablation resulted in improvement of quality‐of‐life metrics irrespective of baseline OSA among AF subtypes.

19 January 2021 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
SAShudhanshu Alishetti
Shudhanshu Alishetti
LBLorenzo Braghieri
Lorenzo Braghieri
DJDouglas L Jennings
Douglas L Jennings
NUNir Uriel
Nir Uriel
PCPaolo C Colombo
Paolo C Colombo
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya
Though left ventricular assist devices (LVADs) are an increasingly common therapy for ACC/AHA Stage D heart failure, the optimal medical therapy for patients with LVADs is not known. We sought to evaluate the safety and efficacy of angiotensin receptor neprilysin inhibitor (ARNi) therapy in our single center LVAD patient experience. We evaluated patients implanted with LVADs at Columbia University Irving Medical Center between August 2010 and May 2019, and who were treated with an ARNi for at least 3 months. Thirty patients met this criteria. Eighteen (60%) patients transitioned to an ARNi from an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), while all were on a beta blocker (BB) at the time of ARNi initiation. The primary outcome, NT-proBNP levels at time of initiation and 3 and 6 month follow up, significantly decreased from a median of 1265 pg/mL at initiation to 750 pg/mL at 3 months and 764 pg/mL at 6 months (p = 0.01). No significant change was seen in serum creatinine, BUN, or potassium levels.